{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:17:49Z","timestamp":1794471469724,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-023-00550-x","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T16:02:05Z","timestamp":1685116925000},"page":"754-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias"],"prefix":"10.1038","volume":"4","author":[{"given":"Ricardo","family":"de Matos Simoes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shirasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondra L.","family":"Downey-Kopyscinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2338","authenticated-orcid":false,"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9","family":"Dup\u00e9r\u00e9-Richer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-2140","authenticated-orcid":false,"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Dhimolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Dashevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-0516","authenticated-orcid":false,"given":"Jordan G.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neekesh V.","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hengeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna B.","family":"Br\u00fcggenthies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-6203","authenticated-orcid":false,"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinlan L.","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":false,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Glassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-7241","authenticated-orcid":false,"given":"Christopher J.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2718-4415","authenticated-orcid":false,"given":"James E.","family":"Bradner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-7399","authenticated-orcid":false,"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W. J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7403","authenticated-orcid":false,"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-9734","authenticated-orcid":false,"given":"Aedin C.","family":"Culhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-480X","authenticated-orcid":false,"given":"James M.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-9576","authenticated-orcid":false,"given":"Joshua M.","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-1369","authenticated-orcid":false,"given":"Jonathan D.","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-9791","authenticated-orcid":false,"given":"William C.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2857-4685","authenticated-orcid":false,"given":"Francisca","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3797-1877","authenticated-orcid":false,"given":"Aviad","family":"Tsherniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-8005","authenticated-orcid":false,"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"550_CR1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","volume":"124","author":"LH Boise","year":"2014","unstructured":"Boise, L. H., Kaufman, J. L., Bahlis, N. J., Lonial, S. & Lee, K. P. The Tao of myeloma. Blood 124, 1873\u20131879 (2014).","journal-title":"Blood"},{"key":"550_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G., Gupta, V. A., Vertino, P. M. & Boise, L. H. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front. Immunol. 10, 1121 (2019).","journal-title":"Front. Immunol."},{"key":"550_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis, M. et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 3, 862\u2013869 (2013).","journal-title":"Cancer Discov."},{"key":"550_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 e16 (2017).","journal-title":"Cell"},{"key":"550_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226\u2013231 (2008).","journal-title":"Nature"},{"key":"550_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nsmb.3458","volume":"24","author":"F Hong","year":"2017","unstructured":"Hong, F. et al. CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response. Nat. Struct. Mol. Biol. 24, 834\u2013839 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"30686","DOI":"10.1074\/jbc.M101725200","volume":"276","author":"AM Khatib","year":"2001","unstructured":"Khatib, A. M. et al. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J. Biol. Chem. 276, 30686\u201330693 (2001).","journal-title":"J. Biol. Chem."},{"key":"550_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-4924-2-28","volume":"2","author":"SA Hawley","year":"2003","unstructured":"Hawley, S. A. et al. Complexes between the LKB1 tumor suppressor, STRAD alpha\/beta and MO25 alpha\/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).","journal-title":"J. Biol."},{"key":"550_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.molcel.2018.02.011","volume":"69","author":"Y Tarumoto","year":"2018","unstructured":"Tarumoto, Y. et al. LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia. Mol. Cell 69, 1017\u20131027 e6 (2018).","journal-title":"Mol. Cell"},{"key":"550_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.2112","volume":"16","author":"DW McMillin","year":"2010","unstructured":"McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483\u2013489 (2010).","journal-title":"Nat. Med."},{"key":"550_CR11","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1182\/blood-2011-04-348490","volume":"119","author":"DW McMillin","year":"2012","unstructured":"McMillin, D. W. et al. Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. Blood 119, e131\u2013e138 (2012).","journal-title":"Blood"},{"key":"550_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd3870","volume":"12","author":"DW McMillin","year":"2013","unstructured":"McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour\u2013stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217\u2013228 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"550_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 1, 258\u2013273 (2020).","journal-title":"Blood Cancer Discov."},{"key":"550_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"550_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature10688","volume":"481","author":"S Duan","year":"2012","unstructured":"Duan, S. et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481, 90\u201393 (2012).","journal-title":"Nature"},{"key":"550_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1084\/jem.20052204","volume":"203","author":"L Pasqualucci","year":"2006","unstructured":"Pasqualucci, L. et al. Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311\u2013317 (2006).","journal-title":"J. Exp. Med."},{"key":"550_CR17","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske, E. P., Jozwiak, S., Kingswood, J. C., Sampson, J. R. & Thiele, E. A. Tuberous sclerosis complex. Nat. Rev. Dis. Primers 2, 16035 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"550_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.molcel.2007.12.023","volume":"29","author":"U Ozcan","year":"2008","unstructured":"Ozcan, U. et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29, 541\u2013551 (2008).","journal-title":"Mol. Cell"},{"key":"550_CR19","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","volume":"132","author":"PL Fedele","year":"2018","unstructured":"Fedele, P. L. et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood 132, 2166\u20132178 (2018).","journal-title":"Blood"},{"key":"550_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"550_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"550_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto, J. et al. ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nat. Chem. Biol. 16, 1208\u20131217 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"550_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An, J. et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. Nat. Commun. 8, 15398 (2017).","journal-title":"Nat. Commun."},{"key":"550_CR24","doi-asserted-by":"publisher","first-page":"e38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duaneradial ray syndrome. eLife 7, e38430 (2018).","journal-title":"eLife"},{"key":"550_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner, R. et al. Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med. 22, 735\u2013743 (2016).","journal-title":"Nat. Med."},{"key":"550_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood-2016-09-738500","volume":"129","author":"T Hideshima","year":"2017","unstructured":"Hideshima, T. et al. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood 129, 1308\u20131319 (2017).","journal-title":"Blood"},{"key":"550_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"550_CR28","doi-asserted-by":"publisher","first-page":"10625","DOI":"10.1073\/pnas.1611751113","volume":"113","author":"D Millrine","year":"2016","unstructured":"Millrine, D., Tei, M., Gemechu, Y. & Kishimoto, T. Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Proc. Natl Acad. Sci. USA 113, 10625\u201310630 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"550_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm.4127","volume":"22","author":"J Fang","year":"2016","unstructured":"Fang, J. et al. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nat. Med. 22, 727\u2013734 (2016).","journal-title":"Nat. Med."},{"key":"550_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J. Med. Chem. 61, 535\u2013542 (2018).","journal-title":"J. Med. Chem."},{"key":"550_CR31","doi-asserted-by":"publisher","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","journal-title":"Science"},{"key":"550_CR32","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","volume":"81","author":"M Heider","year":"2021","unstructured":"Heider, M. et al. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol. Cell 81, 1170\u20131186 e10 (2021).","journal-title":"Mol. Cell"},{"key":"550_CR33","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades, N. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374\u201314379 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"550_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","volume":"5","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades, C. S. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5, 221\u2013230 (2004).","journal-title":"Cancer Cell"},{"key":"550_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"550_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2020-142651","volume":"136","author":"O Dashevsky","year":"2020","unstructured":"Dashevsky, O. et al. Use of olfactory receptor genes as controls for genome-scale CRISPR functional genomic studies to define treatment resistance mechanisms. Blood 136, 36\u201336 (2020).","journal-title":"Blood"},{"key":"550_CR37","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1021\/acs.jmedchem.6b00668","volume":"59","author":"R Ferreira de Freitas","year":"2016","unstructured":"Ferreira de Freitas, R. et al. Discovery of a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor by virtual screening. J. Med. Chem. 59, 6838\u20136847 (2016).","journal-title":"J. Med. Chem."},{"key":"550_CR38","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1021\/acs.jmedchem.6b01033","volume":"59","author":"Y Shen","year":"2016","unstructured":"Shen, Y. et al. Discovery of a potent, selective, and cell-active dual inhibitor of protein arginine methyltransferase 4 and protein arginine methyltransferase 6. J. Med. Chem. 59, 9124\u20139139 (2016).","journal-title":"J. Med. Chem."},{"key":"550_CR39","doi-asserted-by":"publisher","first-page":"14592","DOI":"10.1073\/pnas.1200037109","volume":"109","author":"L Cunningham","year":"2012","unstructured":"Cunningham, L. et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1\u2013CBF\u03b2 interaction. Proc. Natl Acad. Sci. USA 109, 14592\u201314597 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"550_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.onc.1210637","volume":"27","author":"C Zhao","year":"2008","unstructured":"Zhao, C. et al. POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17. Oncogene 27, 63\u201375 (2008).","journal-title":"Oncogene"},{"key":"550_CR41","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","volume":"129","author":"L Jahn","year":"2017","unstructured":"Jahn, L. et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood 129, 1284\u20131295 (2017).","journal-title":"Blood"},{"key":"550_CR42","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3109\/10428194.2010.548535","volume":"52","author":"I Toman","year":"2011","unstructured":"Toman, I. et al. Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics. Leuk. Lymphoma 52, 659\u2013667 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"550_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1541-7786.MCR-17-0606","volume":"16","author":"PS Gowda","year":"2018","unstructured":"Gowda, P. S. et al. Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression. Mol. Cancer Res. 16, 1138\u20131148 (2018).","journal-title":"Mol. Cancer Res."},{"key":"550_CR44","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907\u20134916 (2006).","journal-title":"Blood"},{"key":"550_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11786","volume":"7","author":"RT Timms","year":"2016","unstructured":"Timms, R. T. et al. Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens. Nat. Commun. 7, 11786 (2016).","journal-title":"Nat. Commun."},{"key":"550_CR46","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1182\/blood-2012-03-414920","volume":"120","author":"RW Groen","year":"2012","unstructured":"Groen, R. W. et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120, e9\u2013e16 (2012).","journal-title":"Blood"},{"key":"550_CR47","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"550_CR48","doi-asserted-by":"crossref","unstructured":"Panobinostat approved for multiple myeloma. Cancer Discov. 5, OF4 (2015).","DOI":"10.1158\/2159-8290.CD-NB2015-040"},{"key":"550_CR49","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41375-019-0482-0","volume":"33","author":"MS Raab","year":"2019","unstructured":"Raab, M. S. et al. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and\/or refractory multiple myeloma. Leukemia 33, 2924\u20132933 (2019).","journal-title":"Leukemia"},{"key":"550_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3324\/haematol.2018.191262","volume":"104","author":"K Ishiguro","year":"2019","unstructured":"Ishiguro, K. et al. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica 104, 155\u2013165 (2019).","journal-title":"Haematologica"},{"key":"550_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18446-z","volume":"7","author":"AE Drew","year":"2017","unstructured":"Drew, A. E. et al. Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma. Sci Rep. 7, 17993 (2017).","journal-title":"Sci Rep."},{"key":"550_CR52","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1080\/10428194.2017.1283029","volume":"58","author":"S Nagel","year":"2017","unstructured":"Nagel, S. et al. Identification of a tumor suppressor network in T-cell leukemia. Leuk. Lymphoma 58, 2196\u20132207 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"550_CR53","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41588-021-00889-w","volume":"53","author":"M Sheffer","year":"2021","unstructured":"Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat. Genet. 53, 1196\u20131206 (2021).","journal-title":"Nat. Genet."},{"key":"550_CR54","doi-asserted-by":"publisher","unstructured":"Dufva, O. et al. Single-cell functional genomics of natural killer cell evasion in blood cancers. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.08.22.504722 (2022).","DOI":"10.1101\/2022.08.22.504722"},{"key":"550_CR55","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"550_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06916-5","volume":"9","author":"JM McFarland","year":"2018","unstructured":"McFarland, J. M. et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat. Commun. 9, 4610 (2018).","journal-title":"Nat. Commun."},{"key":"550_CR57","doi-asserted-by":"publisher","unstructured":"Dempster, J. M. et al. Extracting biological insights from the Project Achilles genome-scale CRISPR screens in cancer cell lines. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/720243 (2019).","DOI":"10.1101\/720243"},{"key":"550_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2014.35","volume":"1","author":"GS Cowley","year":"2014","unstructured":"Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).","journal-title":"Sci. Data"},{"key":"550_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"550_CR60","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cell.2017.07.005","volume":"170","author":"ER McDonald 3rd","year":"2017","unstructured":"McDonald, E. R. 3rd et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577\u2013592 e10 (2017).","journal-title":"Cell"},{"key":"550_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"550_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"550_CR63","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"550_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP\u2013seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"550_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45839-z","volume":"9","author":"HM Amemiya","year":"2019","unstructured":"Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE Blacklist: identification of problematic regions of the genome. Sci Rep. 9, 9354 (2019).","journal-title":"Sci Rep."},{"key":"550_CR66","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"550_CR67","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","volume":"45","author":"D Szklarczyk","year":"2017","unstructured":"Szklarczyk, D. et al. The STRING database in 2017: quality-controlled protein\u2013protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362\u2013D368 (2017).","journal-title":"Nucleic Acids Res."},{"key":"550_CR68","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature21688","volume":"543","author":"MA Erb","year":"2017","unstructured":"Erb, M. A. et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543, 270\u2013274 (2017).","journal-title":"Nature"},{"key":"550_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","volume":"14","author":"B Nabet","year":"2018","unstructured":"Nabet, B. et al. The dTAG system for immediate and target-specific protein degradation. Nat. Chem. Biol. 14, 431\u2013441 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"550_CR70","doi-asserted-by":"publisher","first-page":"108532","DOI":"10.1016\/j.celrep.2020.108532","volume":"34","author":"R Shirasaki","year":"2021","unstructured":"Shirasaki, R. et al. Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins. Cell Rep. 34, 108532 (2021).","journal-title":"Cell Rep."},{"key":"550_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00550-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00550-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00550-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T16:07:21Z","timestamp":1685117241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00550-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00550-x","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"16 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. serves research funding from FIMECS and honoraria from Janssen Pharma. G.M.M. is an employee of Aculeus Therapeutics. N.V.D. is an employee of Genentech, a member of the Roche Group. A.J.A. has consulted for Anji Pharmaceuticals, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Oncorus, Inc., Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Plexium, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals and T-knife Therapeutics. A.J.A. holds equity in Riva Therapeutics. A.J.A. has research funding from Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. C.J.O. has received research support from Gilead, Scorpion Therapeutics and eFFECTOR Therapeutics. J.M.D. is a consultant and holds equity in Jumble Therapeutics. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche) and C4 Therapeutics and is the inventor on intellectual property licensed to these entities. J.E.B. has recently served as an executive and shareholder in Novartis AG. N.K. is currently an employee of Kymera Therapeutics, Inc. N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. J.J.K. has received research funding from Amgen, Genentech and Janssen. J.M.M. has received research funding from the Dependency Map Consortium. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, MPM Capital, KSQ Therapeutics, Frontier Medicines, Tyra Biosciences, Function Oncology, Jubilant Therapeutics, Riva Therapeutics, RAPPTA Therapeutics, Calyx and Serinus Biosciences. L.H.B. is a consultant for and receives honoraria and research funding from AstraZeneca, and is a consultant for Genentech and Abbvie. J.D.L. receives research funding from Ipsen\/Epizyme and is consultant for AstraZeneca. A.T. is a consultant for Cedilla Therapeutics, Foghorn Therapeutics and The Center for Protein Degradation (Deerfield), and is a SAB member and holds equity in Turbine Simulated Cell Technologies. F.V. receives research support from the Dependency Map Consortium, Bristol Myers Squibb, Novo Ventures and Riva Therapeutics, and has shares and is a consultant for Riva Therapeutics. C.S.M. serves on the Scientific Advisory Board of Adicet Bio and discloses consultant\/honoraria from Genentech, Fate Therapeutics, Ionis Pharmaceuticals, FIMECS, Secura Bio and Oncopeptides, and research funding from Janssen\/Johnson & Johnson, EMD Serono, Arch Oncology, Karyopharm, Sanofi, Nurix, BMS, H3 Biomedicine\/Eisai, Springworks, Abcuro and Novartis. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}